Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms.

Xiao S, Xue H, Li G, Yuan C, Li X, Chen C, Wu HZ, Mitchell P, Zhang M

The Australian and New Zealand journal of psychiatry1 Feb 2012Cited by 12 (Europe PMC)

PMID22311531DOI10.1177/0004867411433213PepBankPUB-22311531

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In schizophrenia patients, psychiatric symptoms improved in both cerebrolysin and placebo groups receiving risperidone.
In plain wordsIn patients with schizophrenia, psychiatric symptoms improved in both groups, including placebo with risperidone.
Peptide
Cerebrolysin
Outcome
DecreasePANSS psychiatric symptoms over trial
Study
n = 109
Outcome group
Psychiatric symptoms · Mental health and mood
Studied dose
30 ml once daily Monday to Friday · intravenous infusion · 4 weeksAs given in this study (human).
Source sentences
Summary
Patients in both groups demonstrated improvements in psychiatric symptoms and cognitive and memory performance as assessed by PANSS, mWAIS, and WMS over the trial.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 109 patients who met the DSM-IV diagnostic criteria for schizophrenia were randomly assigned to cerebrolysin (cerebrolysin plus risperidone, n=55) or placebo (risperidone only, n=54) groups.
Summary · context
Intravenous infusions of 30 ml cerebrolysin or placebo were given once daily from Monday to Friday for 4 weeks.
Report a problemFND-2231153101
02HumanRandomized controlled trialEfficacy outcome
In schizophrenia patients, cognitive performance improved in both cerebrolysin and placebo groups receiving risperidone.
In plain wordsIn patients with schizophrenia, cognitive performance improved in both groups, including placebo with risperidone.
Peptide
Cerebrolysin
Outcome
IncreasemWAIS cognitive performance over trial
Study
n = 109
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30 ml once daily Monday to Friday · intravenous infusion · 4 weeksAs given in this study (human).
Source sentences
Summary
Patients in both groups demonstrated improvements in psychiatric symptoms and cognitive and memory performance as assessed by PANSS, mWAIS, and WMS over the trial.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 109 patients who met the DSM-IV diagnostic criteria for schizophrenia were randomly assigned to cerebrolysin (cerebrolysin plus risperidone, n=55) or placebo (risperidone only, n=54) groups.
Summary · context
Intravenous infusions of 30 ml cerebrolysin or placebo were given once daily from Monday to Friday for 4 weeks.
Report a problemFND-2231153102
03HumanRandomized controlled trialEfficacy outcome
In schizophrenia patients, memory performance improved in both cerebrolysin and placebo groups receiving risperidone.
In plain wordsIn patients with schizophrenia, memory performance improved in both groups, including placebo with risperidone.
Peptide
Cerebrolysin
Outcome
IncreaseWMS memory performance over trial
Study
n = 109
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30 ml once daily Monday to Friday · intravenous infusion · 4 weeksAs given in this study (human).
Source sentences
Summary
Patients in both groups demonstrated improvements in psychiatric symptoms and cognitive and memory performance as assessed by PANSS, mWAIS, and WMS over the trial.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 109 patients who met the DSM-IV diagnostic criteria for schizophrenia were randomly assigned to cerebrolysin (cerebrolysin plus risperidone, n=55) or placebo (risperidone only, n=54) groups.
Summary · context
Intravenous infusions of 30 ml cerebrolysin or placebo were given once daily from Monday to Friday for 4 weeks.
Report a problemFND-2231153103
04HumanRandomized controlled trialEfficacy outcome
In schizophrenia patients, PANSS total score change did not differ between cerebrolysin plus risperidone and placebo plus risperidone.
In plain wordsIn patients with schizophrenia, total symptom score changes were similar with cerebrolysin and placebo, both with risperidone.
Peptide
Cerebrolysin
Outcome
No significant changePANSS total score change
Study
n = 109
Comparator
Risperidone only with placebo
Outcome group
Psychiatric symptoms · Mental health and mood
Studied dose
30 ml once daily Monday to Friday · intravenous infusion · 4 weeksAs given in this study (human).
Source sentences
Summary
There was no difference in rates of change in the PANSS total score or negative score between the two treatment groups.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 109 patients who met the DSM-IV diagnostic criteria for schizophrenia were randomly assigned to cerebrolysin (cerebrolysin plus risperidone, n=55) or placebo (risperidone only, n=54) groups.
Summary · context
Intravenous infusions of 30 ml cerebrolysin or placebo were given once daily from Monday to Friday for 4 weeks.
Report a problemFND-2231153104
05HumanRandomized controlled trialEfficacy outcome
In schizophrenia patients, PANSS negative score change did not differ between cerebrolysin plus risperidone and placebo plus risperidone.
In plain wordsIn patients with schizophrenia, negative symptom score changes were similar with cerebrolysin and placebo, both with risperidone.
Peptide
Cerebrolysin
Outcome
No significant changePANSS negative score change
Study
n = 109
Comparator
Risperidone only with placebo
Outcome group
Psychiatric symptoms · Mental health and mood
Studied dose
30 ml once daily Monday to Friday · intravenous infusion · 4 weeksAs given in this study (human).
Source sentences
Summary
There was no difference in rates of change in the PANSS total score or negative score between the two treatment groups.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 109 patients who met the DSM-IV diagnostic criteria for schizophrenia were randomly assigned to cerebrolysin (cerebrolysin plus risperidone, n=55) or placebo (risperidone only, n=54) groups.
Summary · context
Intravenous infusions of 30 ml cerebrolysin or placebo were given once daily from Monday to Friday for 4 weeks.
Report a problemFND-2231153105
06HumanRandomized controlled trialEfficacy outcome
In schizophrenia patients, cerebrolysin plus risperidone improved cognitive function more than placebo plus risperidone from week 2.
In plain wordsIn patients with schizophrenia, cerebrolysin improved cognition more than placebo from week 2, both with risperidone.
Peptide
Cerebrolysin
Outcome
IncreaseCognitive function from week 2
Study
n = 109
Comparator
Risperidone only with placebo
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30 ml once daily Monday to Friday · intravenous infusion · 4 weeksAs given in this study (human).
Source sentences
Summary
Patients treated with cerebrolysin showed significantly greater improvements in cognitive and memory function from week 2.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 109 patients who met the DSM-IV diagnostic criteria for schizophrenia were randomly assigned to cerebrolysin (cerebrolysin plus risperidone, n=55) or placebo (risperidone only, n=54) groups.
Summary · context
Intravenous infusions of 30 ml cerebrolysin or placebo were given once daily from Monday to Friday for 4 weeks.
Report a problemFND-2231153106
07HumanRandomized controlled trialEfficacy outcome
In schizophrenia patients, cerebrolysin plus risperidone improved memory function more than placebo plus risperidone from week 2.
In plain wordsIn patients with schizophrenia, cerebrolysin improved memory more than placebo from week 2, both with risperidone.
Peptide
Cerebrolysin
Outcome
IncreaseMemory function from week 2
Study
n = 109
Comparator
Risperidone only with placebo
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30 ml once daily Monday to Friday · intravenous infusion · 4 weeksAs given in this study (human).
Source sentences
Summary
Patients treated with cerebrolysin showed significantly greater improvements in cognitive and memory function from week 2.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 109 patients who met the DSM-IV diagnostic criteria for schizophrenia were randomly assigned to cerebrolysin (cerebrolysin plus risperidone, n=55) or placebo (risperidone only, n=54) groups.
Summary · context
Intravenous infusions of 30 ml cerebrolysin or placebo were given once daily from Monday to Friday for 4 weeks.
Report a problemFND-2231153107
08HumanRandomized controlled trialSafety outcome
In schizophrenia patients, no severe treatment adverse events occurred with cerebrolysin plus risperidone or placebo plus risperidone.
In plain wordsIn patients with schizophrenia, neither cerebrolysin nor placebo groups had severe treatment adverse events, both with risperidone.
Peptide
Cerebrolysin
Outcome
Not applicableSevere treatment adverse events
Study
n = 109
Comparator
Risperidone only with placebo
Outcome group
Adverse events · Whole body
Studied dose
30 ml once daily Monday to Friday · intravenous infusion · 4 weeksAs given in this study (human).
Source sentences
Summary
No severe treatment adverse events were observed in either group.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 109 patients who met the DSM-IV diagnostic criteria for schizophrenia were randomly assigned to cerebrolysin (cerebrolysin plus risperidone, n=55) or placebo (risperidone only, n=54) groups.
Summary · context
Intravenous infusions of 30 ml cerebrolysin or placebo were given once daily from Monday to Friday for 4 weeks.
Report a problemFND-2231153108
09HumanRandomized controlled trialSafety outcome
In schizophrenia patients, adverse event frequency was comparable between cerebrolysin plus risperidone and placebo plus risperidone at treatment end.
In plain wordsIn patients with schizophrenia, adverse event frequency was similar with cerebrolysin and placebo, both with risperidone.
Peptide
Cerebrolysin
Outcome
No significant changeAdverse event frequency
Study
n = 109
Comparator
Risperidone only with placebo
Outcome group
Adverse events · Whole body
Studied dose
30 ml once daily Monday to Friday · intravenous infusion · 4 weeksAs given in this study (human).
Source sentences
Summary
The frequency of adverse events was comparable between the two groups at the end of the treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 109 patients who met the DSM-IV diagnostic criteria for schizophrenia were randomly assigned to cerebrolysin (cerebrolysin plus risperidone, n=55) or placebo (risperidone only, n=54) groups.
Summary · context
Intravenous infusions of 30 ml cerebrolysin or placebo were given once daily from Monday to Friday for 4 weeks.
Report a problemFND-2231153109

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.